Wall Street brokerages expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to announce $59.29 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest sales estimate is $53.29 million and the highest is $66.03 million. Enanta Pharmaceuticals posted sales of $67.21 million in the same quarter last year, which suggests a negative year over year growth rate of 11.8%. The company is scheduled to report its next quarterly earnings report on Monday, November 25th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $213.18 million for the current fiscal year, with estimates ranging from $207.17 million to $219.91 million. For the next year, analysts forecast that the firm will report sales of $196.27 million, with estimates ranging from $189.92 million to $202.82 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.27. The firm had revenue of $44.40 million for the quarter, compared to analyst estimates of $46.98 million. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. Enanta Pharmaceuticals’s quarterly revenue was down 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.97 earnings per share.
ENTA traded down $0.83 on Friday, reaching $69.92. 137,003 shares of the company’s stock were exchanged, compared to its average volume of 218,709. The stock has a market cap of $1.42 billion, a PE ratio of 20.09 and a beta of 0.98. Enanta Pharmaceuticals has a twelve month low of $64.08 and a twelve month high of $106.80. The stock’s fifty day moving average price is $77.66 and its 200-day moving average price is $88.98.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace North America L.P. boosted its holdings in Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after purchasing an additional 207,326 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Enanta Pharmaceuticals in the 2nd quarter valued at about $16,686,000. Price T Rowe Associates Inc. MD boosted its holdings in Enanta Pharmaceuticals by 11.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,528,541 shares of the biotechnology company’s stock valued at $128,978,000 after purchasing an additional 159,504 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Enanta Pharmaceuticals by 17.0% in the 1st quarter. Janus Henderson Group PLC now owns 874,397 shares of the biotechnology company’s stock valued at $83,522,000 after purchasing an additional 126,804 shares during the last quarter. Finally, Norges Bank acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at about $7,106,000. Hedge funds and other institutional investors own 89.73% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Recommended Story: Stop Order
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.